SOLO COVID-19 : In vivo & in vitro solutions to evaluate your prophylactic and therapeutic solutions

SOLO COVID-19 is the product of Oncodesign’s pharmacological expertise combined with our agility and societal commitment. This offer was swiftly deployed in 2020, allowing – with rigor and safety – the implementation of specific in vitro and in vivo pharmacology studies to evaluate new prophylactic, therapeutic or vaccinal approaches to combat COVID-19.

Innovative in vitro and in vivo models to evaluate the potential of your products

Fighting SARS-CoV-2 and its variants

Evaluate your treatment strategies to combat COVID-19 and its complications

In collaboration with our partners IDMIT and SEPIA of the CEA, SOLO Covid-19 offers the ability to evaluate the efficacy of new therapeutic options as well as repositioning of pre-existing options.

This offer is based on the use of an integrated panel of biochemical and cellular assays, including animal models, infected with SARS-CoV-2 or modeling inflammatory pulmonary complications.

  • Biochemical assays for Spike S protein binding, SARS-CoV-2 viral protease activities, human ACE2 protein binding and human TMPRSS2 protease activity.
  • Infection tests of human and simian cells by the original SARS-CoV-2 variant and its variants (alpha, beta, gamma and delta) to assess the potential of compounds on viral load, cytopathogenic effect, immune modulation and air-liquid interface.
  • Models of SARS-CoV-2 infection of transgenic mice, or non-lethal native infection of hamsters and non-human primates, using multiple analyses including imaging.
  • Severe inflammatory model of pulmonary fibrosis in mice, to assess the proof of concept of therapeutic solutions oriented in the management and treatment of post-acute respiratory distress syndrome.

Fix a meeting